Lisata Therapeutics, Inc. (0HS8.L)

2.6900 -0.2000 (-6.92%) As of 03:56PM BST. Market open.

Lisata Therapeutics, Inc.

110 Allen Road
2nd Floor
Basking Ridge, NJ 07920
United States
908 842 0100
https://www.lisata.com

Sector(s): 
Industry: 
Full-time employees: 25

Key executives

Name	Title	Pay	Exercised	Year born
Dr. David J. Mazzo B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph.D.	President, CEO & Director	1.16M	N/A	1957
Dr. Kristen K. Buck M.D.	Executive VP of R&D and Chief Medical Officer	938.42k	N/A	1975
Mr. James Nisco	VP of Finance & Treasury	N/A	N/A	N/A
Mr. Tariq Imam	Vice President of Business Development & Operations and Corporate Counsel	N/A	N/A	N/A
Mr. Gregory S. Berkin	Chief Information Officer	N/A	N/A	N/A
Mr. John D. Menditto	Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Gail Holler	Vice President of Human Resources	N/A	N/A	1959
Dr. William K. Sietsema Ph.D.	Vice President of Global Regulatory Affairs	350.55k	N/A	1956

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Corporate governance

Lisata Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.